Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Novo Nordisk Stock Quote

Novo Nordisk (NYSE: NVO)

Price as of May 22, 2024, 4:00 p.m. ET

Novo Nordisk Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
NVO +65.94% +500.20% +43.11% +115,787%
S&P +26.92% +88.55% +13.52% +4,004%

Novo Nordisk Company Info

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

News & Analysis

The Fool has written over 400 articles on Novo Nordisk.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.